05:29 PM EST, 03/03/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) said its new drug application for relacorilant to treat endogenous hypercortisolism, or Cushing's syndrome, was filed by the US Food and Drug Administration.

The application is based on the results of trials showing positive results, the company said Monday in a statement.

The FDA aims to complete its review by Dec. 30, the company said.